Your browser is no longer supported. Please, upgrade your browser.
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E24.37 EPS (ttm)5.11 Insider Own1.10% Shs Outstand75.83M Perf Week3.13%
Market Cap9.55B Forward P/E- EPS next Y-7.15 Insider Trans-20.37% Shs Float66.39M Perf Month4.36%
Income446.60M PEG- EPS next Q-1.74 Inst Own60.80% Short Float4.46% Perf Quarter-2.59%
Sales901.80M P/S10.59 EPS this Y-550.50% Inst Trans-0.57% Short Ratio2.39 Perf Half Y-3.93%
Book/sh34.34 P/B3.63 EPS next Y-254.10% ROA21.90% Target Price162.94 Perf Year46.25%
Cash/sh33.78 P/C3.69 EPS next 5Y- ROE24.10% 52W Range79.31 - 220.20 Perf YTD-18.67%
Dividend- P/FCF19.01 EPS past 5Y-52.50% ROI-21.30% 52W High-43.45% Beta2.24
Dividend %- Quick Ratio26.20 Sales past 5Y23.80% Gross Margin- 52W Low57.00% ATR5.25
Employees410 Current Ratio26.20 Sales Q/Q2046947.70% Oper. Margin49.70% RSI (14)53.02 Volatility4.26% 4.00%
OptionableYes Debt/Eq0.00 EPS Q/Q827.70% Profit Margin49.50% Rel Volume1.32 Prev Close117.42
ShortableYes LT Debt/Eq0.00 EarningsJul 29 AMC Payout0.00% Avg Volume1.24M Price124.52
Recom2.10 SMA202.53% SMA50-0.70% SMA200-8.12% Volume1,637,097 Change6.05%
Jun-14-21Upgrade Citigroup Sell → Neutral $55 → $132
Apr-21-21Upgrade Jefferies Hold → Buy $172
Mar-04-21Initiated JMP Securities Mkt Outperform $160
Dec-10-20Reiterated Needham Buy $105 → $170
Dec-10-20Reiterated Chardan Capital Markets Buy $110 → $166
Dec-10-20Downgrade Jefferies Buy → Hold
Dec-07-20Downgrade Wells Fargo Overweight → Equal Weight $145
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Sep-17-21 09:30AM  
Sep-16-21 07:22AM  
05:55AM  
Sep-12-21 07:57AM  
Sep-10-21 05:50PM  
Sep-09-21 12:37PM  
07:52AM  
Sep-04-21 07:55AM  
Sep-02-21 05:50PM  
Aug-31-21 09:40AM  
Aug-26-21 12:45PM  
Aug-25-21 09:36AM  
Aug-24-21 09:30AM  
Aug-17-21 10:21AM  
Aug-14-21 08:00AM  
Aug-12-21 05:52AM  
Aug-06-21 02:29PM  
Aug-05-21 08:00AM  
Aug-02-21 01:09AM  
Jul-31-21 08:37AM  
Jul-30-21 10:31AM  
Jul-29-21 06:25PM  
05:50PM  
04:30PM  
Jul-24-21 05:33AM  
Jul-23-21 12:33PM  
10:20AM  
Jul-22-21 11:14AM  
Jul-19-21 03:00PM  
Jul-16-21 05:50PM  
11:02AM  
Jul-13-21 10:15AM  
Jul-11-21 07:01AM  
Jul-09-21 04:04PM  
Jul-02-21 12:48PM  
Jun-30-21 06:42AM  
Jun-29-21 11:20AM  
09:55AM  
Jun-28-21 02:36PM  
08:39AM  
03:21AM  
Jun-26-21 01:07PM  
Jun-25-21 02:07PM  
Jun-24-21 11:00AM  
Jun-18-21 05:50PM  
Jun-16-21 11:25AM  
Jun-15-21 08:06AM  
07:15AM  
06:55AM  
04:37AM  
Jun-14-21 10:50AM  
08:20AM  
Jun-11-21 04:12PM  
10:33AM  
03:05AM  
Jun-08-21 05:50PM  
Jun-07-21 07:11AM  
Jun-06-21 12:16PM  
Jun-05-21 08:08AM  
Jun-04-21 07:21AM  
Jun-02-21 05:50PM  
May-27-21 11:31AM  
May-26-21 06:05AM  
May-25-21 04:47PM  
08:00AM  
May-22-21 09:56AM  
06:25AM  
May-12-21 11:00AM  
06:14AM  
May-11-21 12:12PM  
06:40AM  
May-07-21 11:38AM  
06:40AM  
May-06-21 04:01PM  
May-04-21 06:00AM  
May-01-21 06:10AM  
Apr-29-21 10:01PM  
04:17PM  
08:30AM  
03:26AM  
Apr-28-21 04:01PM  
12:18PM  
09:56AM  
Apr-27-21 05:15PM  
04:01PM  
01:53PM  
Apr-26-21 02:47PM  
08:30AM  
Apr-23-21 05:50PM  
08:09AM  
06:35AM  
Apr-21-21 02:54PM  
08:55AM  
08:10AM  
Apr-20-21 04:29PM  
12:31PM  
10:20AM  
07:15AM  
Apr-16-21 03:51PM  
Apr-10-21 08:31AM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Option Exercise17.7525,000443,75026,891Aug 10 08:00 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Sale138.5225,0003,462,9261,891Aug 10 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Option Exercise12.5728,500358,245216,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Sale128.9828,5003,675,939187,719Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Option Exercise12.571,50018,855189,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Sale125.021,500187,530187,719Aug 06 08:00 PM
Bolzon Bradley J PhDDirectorJul 19Sale126.4310,0001,264,348148,831Jul 21 05:21 PM
Novak RodgerPresidentJun 30Sale165.0025,0004,125,000573,007Jul 01 05:43 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4810,0001,524,799158,831Jun 30 06:38 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4820,3753,106,7830Jun 30 06:38 PM
Novak RodgerPresidentJun 21Sale128.6225,0003,215,458623,007Jun 23 05:54 PM
Kulkarni SamarthChief Executive OfficerJun 15Option Exercise12.5730,000377,100217,719Jun 17 05:44 PM
Kulkarni SamarthChief Executive OfficerJun 15Sale126.4330,0003,792,804187,719Jun 17 05:44 PM
Bolzon Bradley J PhDDirectorJun 11Sale126.6110,0001,266,11820,375Jun 15 04:41 PM
Bolzon Bradley J PhDDirectorMar 22Sale132.3730,3744,020,66730,375Mar 24 06:00 PM
Bolzon Bradley J PhDDirectorFeb 19Sale149.11171,00325,497,840168,831Feb 23 04:40 PM
KASINGER JAMES R.General Counsel and SecretaryJan 19Option Exercise51.4927,5001,415,97549,931Jan 20 06:05 PM
KASINGER JAMES R.General Counsel and SecretaryJan 19Sale204.9427,5005,635,94422,431Jan 20 06:05 PM
Klein Lawrence OttoCBO & COOJan 15Option Exercise13.7925,010344,77636,334Jan 20 06:07 PM
Kulkarni SamarthChief Executive OfficerJan 15Option Exercise1.8120,00036,200202,989Jan 20 06:11 PM
Kulkarni SamarthChief Executive OfficerJan 15Sale213.6720,0004,273,311182,989Jan 20 06:11 PM
Klein Lawrence OttoCBO & COOJan 15Sale215.2025,0005,379,94020,000Jan 20 06:07 PM
Kulkarni SamarthChief Executive OfficerDec 29Option Exercise1.8113,80024,978182,989Dec 30 04:02 PM
Ho Tony WExecutive VP, Head of R&DDec 21Option Exercise16.9023,551398,01257,515Dec 22 04:55 PM
Ho Tony WExecutive VP, Head of R&DDec 21Sale149.2323,5513,514,61033,964Dec 22 04:55 PM
Bolzon Bradley J PhDDirectorDec 16Sale148.957,3521,095,089339,834Dec 18 07:12 PM
Bolzon Bradley J PhDDirectorDec 16Sale148.957,6481,139,1770Dec 18 07:12 PM
Kulkarni SamarthChief Executive OfficerDec 10Option Exercise1.8120,00036,200189,189Dec 11 04:05 PM
Kulkarni SamarthChief Executive OfficerDec 10Sale142.2920,0002,845,782169,189Dec 11 04:05 PM
Bolzon Bradley J PhDDirectorDec 10Sale143.3533,0004,730,448314,186Dec 14 07:11 PM
KASINGER JAMES R.General Counsel and SecretaryDec 09Option Exercise13.6222,026299,99422,415Dec 10 04:35 PM
Bolzon Bradley J PhDDirectorDec 07Sale154.53171,00426,424,505347,186Dec 09 07:54 PM
Novak RodgerPresidentNov 30Option Exercise14.21100,0001,421,500698,007Dec 02 04:26 PM
Novak RodgerPresidentNov 30Sale125.00100,00012,500,000648,007Dec 02 04:26 PM
Novak RodgerPresidentOct 09Option Exercise14.432,76239,856650,769Oct 13 04:44 PM
Novak RodgerPresidentOct 09Sale100.002,762276,200648,007Oct 13 04:44 PM
Novak RodgerPresidentOct 08Option Exercise14.4322,238320,894670,245Oct 13 04:44 PM
Novak RodgerPresidentOct 08Sale100.0022,2382,223,800648,007Oct 13 04:44 PM